DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

DBVT has been the topic of a number of other research reports. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. Lifesci Capital upgraded shares of DBV Technologies to a "strong-buy" rating in a research report on Thursday, June 26th. Finally, HC Wainwright raised their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Trading Up 12.0%

Shares of NASDAQ DBVT opened at $11.54 on Friday. The stock has a market cap of $316.05 million, a price-to-earnings ratio of -2.35 and a beta of -0.59. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $12.78. The company's 50-day moving average price is $9.42 and its 200 day moving average price is $6.53.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The business had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. As a group, research analysts expect that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.